Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort | Zendy

Antonio Di Biagio | Zendy; Roberta Prinapori | Zendy; Diana Giannarelli | Zendy; Franco Maggiolo | Zendy; Simona Di Giambenedetto | Zendy; Vanni Borghi | Zendy; Giovanni Penco | Zendy; Paola Cicconi | Zendy; Daniela Francisci | Zendy; Gaetana Sterrantino | Zendy; Alessia Zoncada | Zendy; Laura Monno | Zendy; Amedeo Capetti | Zendy; Andrea Giacometti | Zendy

Open Access

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort

Author(s) -

Antonio Di Biagio,

Roberta Prinapori,

Diana Giannarelli,

Franco Maggiolo,

Simona Di Giambenedetto,

Vanni Borghi,

Giovanni Penco,

Paola Cicconi,

Daniela Francisci,

Gaetana Sterrantino,

Alessia Zoncada,

Laura Monno,

Amedeo Capetti,

Andrea Giacometti

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks339

Subject(s) - lopinavir , emtricitabine , efavirenz , ritonavir , atazanavir , lopinavir/ritonavir , medicine , pharmacology , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load

To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research